Clinical trials: HEPATITIS C VIRUS CHRONIC INFECTION
Hepatitis C Virus (HCV)
Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response
Hepatitis C virus (HCV) infection is among the most common of all chronic liver diseases. HCV predominantly affects liver cells and causes the liver to become inflamed and damaged.
- Trial name
- CHOICE (NCT04577482)
- Where
- 10 sites in Russia
- Volunteers
- 42 people
- Sponsor
- AbbVie
Hepatitis C
Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection
The purpose of this study is to examine gene expression profiles by DNA microarray in patients who are responders and non-responders to interferon and ribavirin treatment for hepatitis C virus (HCV).
- Trial name
- NCT00164073
- Testing
- Liver biopsy
- Where
- Australia
- Volunteers
- 60 people
- Sponsor
- Bayside Health
Hepatitis C, Chronic
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
The purpose of this study is to determine whether low-dose peg-interferon plus ribavirin therapy is effective in the prevention of hepatocellular carcinoma (HCC) in patients who had the curative resection of primary HCC.
- Trial name
- NCT00375661
- Testing
- interferon-alfa-2b and ribavirin
- Where
- 2 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Kyoto University
Chronic Hepatitis C (Disorder)
Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs
Recently,surprisingly and unexpectedly increased aggressiveness and high rates of HCC recurrence (28%(16/58) and 29%(17/59), respectively) have been reported in patients who cleared HCV with DAAs after achieving a complete…
- Trial name
- NCT03063723
- Testing
- Ledipasvir-Sofosbuvir, Daclatasvir-Sofosbuvir
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis C
Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2)
The purpose of this observational study was to provide summary data from participants who relapsed at the end of the follow-up phase after 24 weeks of treatment with standard care PegIntron plus ribavirin in Part 1 of the study…
- Trial name
- NCT01054742
- Testing
- Standard of Care PegIntron, Standard of Care Ribavirin
- Volunteers
- 2 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus
The purpose of this study is to determine the antiviral effect following three days of dosing with BMS-824393 in chronically genotype subtype 1a and 1b Hepatitis C virus (HCV) infected subjects.
- Trial name
- NCT00971308
- Testing
- BMS-824393
- Where
- 6 sites in United States
- Volunteers
- 37 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections, Hepatitis C, Chronic
Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-infected Patients
Combination of PEG interferon and ribavirin is the standard treatment of chronic hepatitis C. Efficacy of this treatment has never been evaluated in HCV-HIV infected patients, who have previously been treated with a first line…
- Conditions
- HIV Infections, Hepatitis C, Chronic, Treatment Failure
- Trial name
- ROCO2 (NCT00221650)
- Testing
- Peginterferon alfa2a, Ribavirin
- Where
- France
- Volunteers
- 17 people
- Sponsor
- University Hospital, Bordeaux
Hepatitis C, Chronic
PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)
This observational study will assess predictors of early on-treatment and sustained virological response in treatment-naïve patients with chronic hepatitis C initiated on treatment with Pegasys (peginterferon alfa-2a) and…
- Trial name
- NCT01070550
- Testing
- Peginterferon alfa-2a (Pegasys®)
- Where
- 266 sites in Austria, Brazil and 12 more
- Volunteers
- 4,680 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic, Cognition Disorders
Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)
Patients with HCV infection often suffer from chronic fatigue, depression and reduced cognition, even before evolving severe liver fibrosis, liver cirrhosis and hepatic encephalopathy.
- Conditions
- Hepatitis C, Chronic, Cognition Disorders, Fatigue Syndrome, Chronic, Major Depressive Disorder
- Trial name
- NCT00788918
- Testing
- Interferon and ribavirin
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Hepatitis C
Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients
1. To asses curability of( Ombitasvir ,Paritaprevir,Ritonavir) in chronic HCV infected patients in those with CKD versus ESRD in Assiut Hospital University . 2.
- Trial name
- NCT03341988
- Testing
- Ombitasvir-Paritaprevir-Ritonavir Tab 12.5-75-50 milligram
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Chronic Hepatitis C
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C
The purpose of this study is to determine if nitazoxanide in combination with peginterferon alfa-2a and ribavirin is safe and effective in treating chronic hepatitis C in patients that have previously failed to respond to…
- Trial name
- STEALTHC-2 (NCT00495391)
- Testing
- Nitazoxanide, Peginterferon alfa-2a, Ribavirin
- Where
- 10 sites in United States
- Volunteers
- 64 people
- Sponsor
- Romark Laboratories L.C.
HCV Infection
Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
The purpose of this study is to assess the safety, tolerability and effectiveness of ANA598 when administered with pegylated interferon and ribavirin (Standard of Care [SOC]) compared to placebo + SOC.
- Trial name
- NCT00978497
- Testing
- ANA598, Peginterferon, Ribavirin
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C
Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)
The study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO) and work productivity data of the interferon-free ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir +/- dasabuvir) +/- Ribavirin…
- Trial name
- REAL (NCT02582658)
- Volunteers
- 173 people
- Sponsor
- AbbVie
Hepatitis C, Medication Adherence
Patient-Centered Models of HCV Care for People Who Inject Drugs
People who inject drugs (PWID) have higher rates of hepatitis C virus (HCV) than do other groups. Effective, safe new treatments called direct-acting antiviral agents (DAAs) have been developed recently.
- Trial name
- HERO (NCT02824640)
- Testing
- Patient Navigation, modified Directly Observed Therapy
- Where
- United States
- Volunteers
- 755 people
- Sponsor
- Prisma Health-Upstate
Hepatitis, Hepatitis C
Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C
The purpose of the study is to demonstrate the noninferiority of Algeron 1.5 and 2.0 μg/kg/week in combination with ribavirin compared to PegIntron in combination with ribavirin in the treatment of chronic hepatitis C, and to…
- Trial name
- NCT01740089
- Testing
- Algeron, PegIntron, Ribavirin
- Where
- Russia
- Volunteers
- 150 people
- Sponsor
- Biocad
Hepatitis C, Chronic
Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)
This study is an open-label, multi-center trial to evaluate the novel 2-drug regimen of uprifosbuvir (MK-3682) 450 mg and ruzasvir (MK-8408) 60 mg in participants with chronic hepatitis C virus (HCV) genotype (GT)1, GT2, GT3…
- Trial name
- NCT02759315
- Testing
- Uprifosbuvir 450 mg, Ruzasvir 60 mg
- Volunteers
- 160 people
- Sponsor
- Merck Sharp & Dohme LLC
Depression in Chronic Hepatitis C
Effects of Direct-acting Antiviral Agents on HCV Cognitive Function, and Depression in HCV Related Cirrhosis: A Prospective Clinical Trial
Minimal hepatic encephalopathy (MHE) is an important clinical variant of hepatic encephalopathy (HE), which occurs in up to 60-70% of patients with cirrhosis.
- Trial name
- NCT04330508
- Testing
- Depression and Cognitive Tests
- Where
- India
- Volunteers
- 385 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Hepatitis C Infection, HIV Infection
Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study
The protocol will study the safety and efficacy of using sofosbuvir and ribavirin for the treatment of hepatitis c in patients taking stribild.
- Trial name
- NCT02220868
- Testing
- Sofosbuvir, Ribavirin, and Stribild
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Saint Michael's Medical Center
Hepatitis C, Chronic, Liver Diseases
Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2)
The purpose of this study is to validate the first round HCV early dynamics discovery within a larger population.
- Conditions
- Hepatitis C, Chronic, Liver Diseases, Interferon Deficiency
- Trial name
- sIFN-pred2 (NCT01760148)
- Testing
- interferon alpha 2b
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Junqi Niu
Hepatitis C, Chronic, Hepatitis C
Epidemiology of Occult Hepatitis C Virus Infection in Patients Born Before 1969 in the Hospital Setting: a Spontaneous Opportunistic Screening Initiative.
The goal of this monocentric prospective observational study is to evaluate the prevalence of unknown hepatitis C virus chronic infection in general population born before january 1st 1968 in Italy.
- Conditions
- Hepatitis C, Chronic, Hepatitis C, Hepatitis
- Trial name
- ERADIcATE (NCT05813691)
- Testing
- Meridan Bioscience Point of Care test against HCV antibodies
- Volunteers
- 4,000 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.